During the past decade, the survival of patients with multiple myeloma (MM) has dramatically improved. This remarkable change is largely due to an increase in the antimyeloma armamentarium, including next-generation proteasome inhibitors (carfilzomib, ixazomib), next-generation immunomodulatory drugs (IMiDs) (pomalidomide) and monoclonal antibodies (elotuzumab, daratumumab). 1 However, the disease still remains incurable in the majority of cases and innovative strategies are therefore needed. BH3
mimetics represent a new class of drug that induce tumor cell death by targeting the antiapoptotic proteins. Venetoclax, the first-in-class oral Bcl-2-specific BH3 mimetic, demonstrated impressive results in Bcl-2 dependent malignancies, such as chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. [2] [3] [4] We previously demonstrated that a subgroup of myeloma cells is Bcl-2 dependent and therefore sensitive to venetoclax in vitro. 5, 6 Interestingly, sensitivity to venetoclax was found to be restricted to the myeloma cells harboring the translocation t(11;14). 5 Here, we describe the case of a young patient with very advanced and refractory MM, who achieved a deep and durable response after venetoclax therapy.
The patient is a 25 year-old woman diagnosed with symptomatic IgG-λ MM in 2010 according to current IMWG criteria. The survival of patients with relapsed MM refractory to bortezomib and lenalidomide is very poor. 9 In the relapsed setting, several novel agents, including pomalidomide, carfilzomib and daratumumab, have improved the prognosis of myeloma patients and have therefore been recently approved by the American and European drug agencies. [10] [11] [12] The present patient presented with end-stage myeloma refractory to bortezomib, lenalidomide, carfilzomib, pomalidomide and daratumumab. Moreover, she harbored a 17p deletion, a very high-risk cytogenetic feature. Despite these very poor characteristics, the patient achieved a deep (VGPR) and durable (at least 6 months) response after venetoclax therapy. For this patient, the duration of response to Ven -Dex was longer than that obtained with pomalidomide, carfilzomib and daratumumab. We previously demonstrated that in vitro sensitivity to venetoclax was restricted to MM cells harboring the translocation t(11;14). 5 Here, we were able to test the in vitro sensitivity of the patient's plasma cells to venetoclax. The LD 50 was found to be in the nanomolar range, as previously observed for sensitive myeloma samples. 5, 6 Of interest, this result confirms the fact that the alteration of the p53 pathway does not impact the sensitivity to venetoclax. Recently, a phase 1 dose-escalation trial evaluated the safety and efficacy of venetoclax as a single agent in relapsed myeloma patients. 13 In the final 1200 mg/day cohort, the maximal tolerated dose was not reached, justifying the dose used for the present patient. In this trial, patients had very advanced disease with a median of 5 prior therapies. For patients with translocation t (11;14) , the overall response rate (ORR) (at least PR) was 40%, including 6% CR and 20% VGPR. For patients without translocation t (11;14) , almost no responses were observed (ORR = 6%). These results are very promising and demonstrate for the first time the clinical activity of a single agent in a specific cytogenetic subgroup of patients. Dexamethasone has been shown to promote Bcl-2 dependence in myeloma cells in vitro.
14 Therefore, we chose to add dexamethasone to venetoclax, even if the patient was refractory to dexamethasone. In conclusion, the present case demonstrates the ability of venetoclax to induce deep and sustained responses in MM patients with translocation t (11;14) , even in a setting of end-stage disease with high-risk 17p deletion. 
